COVID-19 Vaccination Response in Patients with Multiple Sclerosis Treated with Ofatumumab in the United States: A Medical Record Review
Patients with MS receiving ongoing treatment with ofatumumab can mount a positive humoral response to a COVID-19 vaccination. Prior treatment with anti-CD20 or S1P DMTs may be a risk factor for lower humoral response.
Authors
- Rahul Dave (ORCID: https://orcid.org/0000-0003-1926-4105)
- Augusto Miravalle (ORCID: https://orcid.org/0000-0002-3363-6932)
- Abigail Hitchens (ORCID: https://orcid.org/0000-0002-4961-0817)
- Regina Berkovich (ORCID: https://orcid.org/0000-0003-4093-7431)
- Katherine Houghton (ORCID: https://orcid.org/0000-0003-4416-6080)
- Kerri Wyse (ORCID: https://orcid.org/0000-0003-0048-7683)
- Heidi Crayton (ORCID: https://orcid.org/0009-0008-6785-8155)
- Ming-Hui Tai
Institutions
- Novartis (Switzerland) (CH)
- Rush University Medical Center (US)
- LAC+USC Medical Center (US)
- Inova Fairfax Hospital (US)
- Nova Medical (United States) (US)
- RTI Health Solutions (US)
- Multiple Sclerosis Center of Atlanta (US)
- Tris Pharma (United States) (US)
Publication Details
- Journal
- Neurology and Therapy
- Published
- 2024-10-23
- DOI
- https://doi.org/10.1007/s40120-024-00671-0
- Citations
- 1
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- Novartis Pharmaceuticals Corporation